International Journal of Rheumatology / 2013 / Article / Tab 1 / Review Article
Adverse Event Burden, Resource Use, and Costs Associated with Immunosuppressant Medications for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review Table 1 Summary of commonly reported AEs by intervention.
At least 1 AE Infections GI Amenorrhea Hematological Death and/or ovarian complications MMF RCTs (
) 96.2–97.3% 12.5–68.5% 9.1–61.4% 0–6% 0–21.7% 1.9–5.0% Observational (
) 42.8–66.7% 3.85–44.4% 4.2–38.9% N/A 0.5–5.6% N/A MTX RCTs (
) 93.0% 4.9% 56.1% N/A 26.8% N/A Observational (
) N/A N/A N/A N/A N/A N/A AZA RCTs (
) N/A 2.4–42.4% 3.2–21.4% 8–36% 6–50% 0–25% Observational (
) N/A N/A 1.3% 1.4–5.6% 16.7% N/A IVC RCTs (
) 95% 11.8–77% 29.4–66.7% 2.2–56.3% 1.4–38.7% 2.7–20% Observational (
) 57.5–65% 12.5–67.9% 18–58.8% 1.9–58% 2.5–7.7% 3.0–20% Oral CYC RCTs (
) N/A 33–40% 3.2% 36–71% 25.8% 6.5–22.2% Observational (
) N/A 26–61% 7% 28–37% 7% N/A CsA RCTs (
) N/A 6.4–19.4% 17.0–30.6% N/A 11.1–38.3% 4.3% Observational (
) 62.5% N/A 3.9% N/A N/A N/A
AZA: azathioprine; CsA: cyclosporine; CYC: cyclophosphamide; IVC: intravenous cyclophosphamide; MMF: mycophenolate mofetil; MTX: methotrexate; N/A: not available; RCT: randomized controlled trial.
